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OBJECTIVE—Postprandial plasma nonesteriﬁed fatty acid
(NEFA) appearance is increased in type 2 diabetes. Our objective
was to determine whether skeletal muscle uptake of plasma NEFA
is abnormal during the postprandial state in type 2 diabetes.
RESEARCH DESIGN AND METHODS—Thigh muscle blood
ﬂow and oxidative metabolism indexes and NEFA uptake were
determined using positron emission tomography coupled with
computed tomography (PET/CT) with [
11C]acetate and 14(R,S)-
[
18F]ﬂuoro-6-thia-heptadecanoic acid (
18FTHA) in seven healthy
control subjects (CON) and seven subjects with type 2 diabetes
during continuous oral intake of a liquid meal to achieve steady
postprandial NEFA levels with insulin infusion to maintain simi-
lar plasma glucose levels in both groups.
RESULTS—In the postprandial state, plasma NEFA level was
higher in type 2 diabetic subjects versus CON (P , 0.01),
whereas plasma glucose was at the same level in both groups.
Muscle NEFA fractional extraction and blood ﬂow index levels
were 56% (P , 0.05) and 24% (P = 0.27) lower in type 2 di-
abetes, respectively. However, muscle NEFA uptake was sim-
ilar to that of CON (quadriceps femoris [QF] 1.47 6 0.23 vs.
1.37 6 0.24 nmol $ g
21 $ min
21, P = 0.77; biceps femoris [BF] 1.54 6
0.26 vs. 1.46 6 0.28 nmol $ g
21 $ min
21, P = 0.85). Muscle oxidative
metabolism was similar in both groups. Muscle NEFA fractional
extraction and blood ﬂow index were strongly and positively
correlated (r = 0.79, P , 0.005).
CONCLUSIONS—Postprandial muscle NEFA uptake is normal
despite elevated systemic NEFA levels and acute normalization
of plasma glucose in type 2 diabetes. Lower postprandial muscle
blood ﬂow with resulting reduction in muscle NEFA fractional
extraction may explain this phenomenon. Diabetes 60:408–415,
2011
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ncreased intramyocellular triglyceride (IMTG) level
correlates with impaired insulin sensitivity in obese
insulin-resistant subjects and subjects with type 2
diabetes (1). Experimental elevation of plasma
nonesteriﬁed fatty acid (NEFA) in humans using in-
travenous lipid infusion was associated with rapid de-
position of IMTG associated with the development of
insulin resistance within 4 h (2). Similarly, high-fat diet for
3 days in healthy volunteers induced IMTG accumulation
associated with impaired insulin sensitivity (3). It has been
demonstrated that subjects with type 2 diabetes have in-
creased postprandial IMTG deposition (4), but the mech-
anisms leading to this phenomenon have not been
elucidated. Impaired muscle fatty acid oxidation has been
shown during fasting and during exercise in obese insulin-
resistant subjects and subjects with type 2 diabetes (5–7).
However, impaired muscle NEFA oxidation was associ-
ated with impaired NEFA uptake in the later studies, and
suppression of muscle fatty acid oxidation by insulin was
reduced in insulin-resistant individuals (5). During similar
intravenous fat load, NEFA levels were higher in subjects
with impaired glucose tolerance, a phenomenon that is
signiﬁcantly correlated with lipid-induced insulin resis-
tance and impaired b-cell function in vivo (8). We dem-
onstrated that this “impaired NEFA tolerance” during
intravenous fat load is associated with increased whole-
body palmitate oxidation in offspring of parents with type
2 diabetes (9). Recently, we showed that subjects with
type 2 diabetes have increased postprandial NEFA ap-
pearance and whole-body oxidation rates without or with
acute correction of hyperglycemia using intravenous in-
sulin infusion to clamp glucose level (10).
The aim of the current study was to determine whether
postprandial NEFA uptake in thigh skeletal muscles is in-
creased in men with established but well-controlled type 2
diabetes compared with healthy men without a family
history of type 2 diabetes. Our hypothesis was that in-
creased postprandial NEFA appearance is associated with
increased NEFA uptake in thigh skeletal muscle of men
with type 2 diabetes. Our study design also allowed us, as
a secondary objective, to determine postprandial leg sub-
cutaneous adipose tissue NEFA uptake that may be a po-
tential mechanism for increased postprandial plasma
NEFA levels in type 2 diabetes.
RESEARCH DESIGN AND METHODS
Ethics statement. Informed written consent was obtained from all partic-
ipantsinaccordancewiththeDeclarationofHelsinki,andtheprotocolreceived
approval from the Human Ethics Committee of the Centre Hospitalier Université
de Sherbrooke.
Subjects. Seven healthy men without glucose intolerance (controls subjects
[CON]), based on a 75-g oral glucose tolerance test, and seven men with
established type 2 diabetes aged between 18 and 60 years participated in this
metabolic study (Table 1). None of the participants had a current medical
condition known to affect lipid levels or insulin sensitivity (other than type 2
diabetes), and participants had no known cardiovascular disease. Type 2 di-
abetic subjects were well controlled (A1C ,7.5%) on diet alone and/or with
only one oral hypoglycemic agent (sulfonylurea or metformin). Oral hypo-
glycemic and antihypertensive drugs, when taken, were stopped for 2 days
before the study. Capillary blood glucose and blood pressure were monitored
four times a day and daily, respectively, during this period. Statin therapy,
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ORIGINAL ARTICLEwhen present, was stopped for 3 weeks before the study. None of the par-
ticipants were taking thiazolidinediones, ﬁbrates, or b-blockers.
Experimental protocols. Subjects were instructed to follow an isocaloric diet
(0% alcohol, 15% protein, 30% fat, and 55% carbohydrates) 48 h before the
experimental protocol. On arrival, body weight, height, and waist circumfer-
ence were measured and lean body mass was determined by electrical bio-
impedance (Hydra ECF/ICF; Xitron Technologies, San Diego, CA). An
intravenous catheter was placed in one forearm for infusions, and another was
placed in a retrograde fashion in the contralateral wrist vein maintained in
a heating pad (;55°C) for blood sampling.
The metabolic protocol consisted in a steady-state postprandial condition
with a glucose clamp using exogenous insulin infusion, as described previously
(10) (Fig. 1). Continuous oral intake of a standard liquid meal was designed to
achieve steady-state postprandial NEFA and triglyceride (TG) levels over 6 h.
The fat drink was prepared by sonication of soybean oil (54 g/L), safﬂower oil
(54 g/L), dried nonfat milk (263 g/L), egg phospholipids (0.18 g/L), and water
with the addition of chocolate syrup (202 g/L) and sugar (15 g/L) to provide
2,465 kcal/L (39% as fat, 16% as proteins, and 45% as carbohydrates). The
drink’s fatty acid composition was similar to the composition of Intralipid, an
intravenous fat emulsion that we used in previous studies. The oral intake of
the drink corresponded to 28.4 mL every 15 min for a total of 1,680 kcal (74 g fat
and 163 g carbohydrates) over 6 h. During the experimental protocol, plasma
glucose was clamped at ;5.5–6.0 mmol/L over the last 3 h of the 6-h post-
prandial period using a variable dextrose 20% (D20%) intravenous infusion ad-
justed every 5 min, according to plasma glucose level (Beckman Glucose
Analyzer II; Beckman Instruments, Fullerton, CA) during intravenous insulin
infusion (primed 0.8 mU/kg continuous 1.2 mU/kg/min infusion of Novolin,
Toronto, Mississauga, ON). This protocol was performed to control for any
potential effect of the difference in plasma glucose level on postprandial fatty
acid metabolism and tissue fatty acid oxidation (11). We previously demon-
strated that subjects with type 2 diabetes display increased plasma palmitate and
NEFA appearance and oxidation rates during steady-state postprandial condi-
tion without or with the glucose clamp using this insulin infusion protocol (10).
PET/CT acquisitions. The participants were positioned supine in a positron
emission tomography coupled with computed tomography (PET/CT) scanner
(Philips Gemini GXL; Philips, Eindhoven, the Netherlands) using a row action
maximum likelihood algorithm (RAMLA) without sinogram rebinning for
reconstructing images. The other parameters were as follows: isotropic voxel
size of 4 mm, 60-cm diameter by 18-cm axial ﬁeld of view. A CT scan (16 mA) of
thighs was performed to correct for attenuation and for deﬁnition of PET
regions of interests. At time 270 min after the beginning of continuous oral
intake of the liquid meal, ;185 MBq of [
11C]acetate, produced as previously
described (12), was injected intravenously over 30 s followed by dynamic list-
mode acquisition for 30 min (12 3 10, 8 3 30, 4 3 300, and 1 3 240 s) to
quantify thigh tissue blood ﬂow and oxidative metabolism (13). Three partic-
ipants (one CON and two type 2 diabetic subjects) did not receive the [
11C]
acetate because of delayed synthesis time of the tracer. 14(R,S)-[
18F]ﬂuoro-
6-thia-heptadecanoic acid (
18FTHA), a long-chain fatty acid analog that
undergoes initial steps of b-oxidation and is thereafter trapped in the cell, was
produced as previously described (14). Approximately 180 MBq of this tracer
in 5 mL 25% human albumin was administered intravenously over 30 s at time
330 min after the beginning of continuous meal intake followed by dynamic
list-mode acquisition for 30 min (12 3 10, 8 3 30, and 8 3 180 s) to quantify
plasma NEFA uptake of thigh tissues, as previously performed by others
during the fasting state (15). Total radioactivity exposure to the participants
was ,8 mSv. All tracers were pretested for sterility and nonpyrogenicity, and
their use in humans was approved by Health Canada and the Human Ethics
Committee of the Centre Hospitalier Université de Sherbrooke.
The protocols started with 30 min bed rest, after which blood samples were
taken at 10-min intervals at baseline (time 230 to 0 min) and during the
18FTHA
dynamic imaging protocols (time 330–360 min after the beginning of contin-
uous meal intake) (Fig. 1). Blood was collected in tubes containing Na2EDTA
and Orlistat (30 mg/mL; Roche, Mississauga, Canada) to prevent in vitro TG
lipolysis (16).
Laboratory assays. Glucose, insulin, total NEFA, and TGs were measured as
described (9). Fractional plasma
18FTHA and metabolites were determined by
thin-layer chromatography, as previously described (17).
PET/CT images analysis. All image-derived input functions and the full-width
at half-maximum were drawn on both the left and right femoral arteries over
three consecutive planes, with an interval of 4 cm between planes. Corrections
were applied on input function for partial volume and tissue-to-artery spill-in of
radioactivity as described previously (18). The maximum value of the four
highest adjacent pixels (standard uptake value peak) for each frame was
recorded. Regions of interest were drawn on the skeletal muscle (quadriceps
femoris [QF] and biceps femoris [BF], e.g., predominantly white and red
muscle ﬁbers, respectively) and subcutaneous fat of the femoral region to
generate tissue time-radioactivity curves (Supplementary Fig. 1B), as recently
performed by others to determine adipose tissue NEFA uptake during fasting
(19). The regions of interest were ﬁrst deﬁned from the transaxial CT slices
and then copied to both the [
11C]acetate and
18FTHA image sequences. Large
vessels were avoided when outlining the muscle areas.
Calculations. Muscle blood ﬂow index (the ﬁrst-pass tissue fractional ex-
traction, K1 in min
21,o f[
11C]acetate) and muscle oxidative metabolism index
(the rapid fractional tissue clearance, k2 in min
21,o f[
11C]acetate) were esti-
mated from [
11C]acetate using a three-compartment model (13,20,21), as
previously published by our group (18). At relatively low tissue blood ﬂow rate
as occurring in resting skeletal muscles, ﬁrst-pass tissue fractional extraction
of arterial [
11C]acetate is close to 1 and provides a reliable index of tissue
perfusion (22). Determination of tissue oxidative metabolism using the [
11C]
acetate method is based on the following assumptions (13): 1) acetate enters
the Krebs cycle freely after rapid conversion into acetyl-CoA; 2) other acetate
metabolic pathways (e.g., de novo lipogenesis, amino acid transcarboxylation)
are relatively slow compared with the Krebs cycle carbon ﬂuxes; 3) carbon
ﬂuxes into the Krebs cycle through acetyl-CoA is directly coupled with the
production of reducing equivalents; 4) the Krebs cycle contribution to the
production of reducing equivalents is stable and accounts for approximately
two-thirds of total production; and 5) the production of reducing equivalents is
tightly coupled with oxygen consumption.
The nonmetabolized fraction of
18FTHA was used to correct the plasma
input function (Supplementary Fig. 1A) and plasma and femoral tissue time-
radioactivity curves were analyzed graphically using the Patlak linearization
method (Supplementary Fig. 1C) (17,18). The slope of the plot in the graphical
analysis is equal to the tissue NEFA fractional extraction constant of
18FTHA
(Ki). Ki was corrected for tissue density by multiplying the constant by the
appropriate density (skeletal muscle: 1.0597 g/mL; adipose tissue: 0.9196
g/mL). Tissue NEFA uptake was calculated by multiplying Ki by mean plasma
NEFA concentration during
18FTHA PET imaging protocol, with a lumped
constant of 1 when compared with endogenous plasma NEFA.
Statistical analysis. Data are expressed as mean 6 SEM. Unpaired Student
t test was used to compare characteristics between CON and type 2 diabetic
subjects. Two-way ANOVA with group, time, and interaction as independent
variables was used to analyze differences in plasma glucose, insulin, NEFA,
and TGs throughout the protocol. Spearman correlation coefﬁcients were
used to determine correlation between variables. A two-tailed P value of ,0.05
was considered signiﬁcant. All analyses were performed with the SAS soft-
ware for Windows, version 9.1.3 (SAS Institute, Cary, NC) or GraphPad Prism
version 5.00 for Windows (San Diego, CA).
RESULTS
Participant characteristics and plasma metabolites
and insulin levels. Type 2 diabetic subjects were older
and tended to have higher body fat than CON. Type 2 di-
abetic subjects also had signiﬁcantly higher fasting plasma
TABLE 1
Characteristics of the participants
CON Type 2 diabetes P*
n 77
Age (years) 35 6 55 0 6 5 0.04
BMI (kg/m2) 27.6 6 1.2 30.1 6 2.3 0.36
Weight (kg) 86.6 6 3.3 93.5 6 9.3 0.49
Lean weight (kg) 65.8 6 3.0 62.5 6 4.4 0.55
Nonlean weight (kg) 20.8 6 2.8 31.0 6 5.3 0.11
Fat percent (%) 23.9 6 2.8 32.1 6 2.4 0.10
Fasting glucose (mmol/L) 5.1 6 0.1 6.5 6 0.3 0.001
Fasting insulin (pmol/L) 65 6 16 140 6 37 0.09
Fasting NEFA (µmol/L) 278 6 34 370 6 46 0.13
Fasting TG (mmol/L) 1.05 6 0.21 1.35 6 0.42 0.54
Fasting cholesterol
(mmol/L) 4.30 6 0.34 4.79 6 0.23 0.26
Fasting HDL cholesterol
(mmol/L) 1.40 6 0.21 1.14 6 0.13 0.31
Fasting LDL
cholesterol (mmol/L) 2.30 6 0.38 3.18 6 0.19 0.07
Data are means 6 SEM. *From the unpaired Student t test.
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insulin, NEFA, and LDL cholesterol levels.
Plasma glucose was higher in type 2 diabetic subjects
than in CON throughout the metabolic study (Fig. 2A)
(ANOVA P , 0.01) with signiﬁcant group 3 time in-
teraction due to the clamp procedure in the last 3 h that
abolished difference between the two groups during the
PET/CT acquisition period (ANOVA P = 0.45). Plasma in-
sulin, NEFA, and TGs (Fig. 2B, C,a n dD, respectively)
were also signiﬁcantly higher in type 2 diabetic subjects
than in CON (all ANOVA P , 0.01) without signiﬁcant
group 3 time interaction.
Skeletal muscle blood ﬂow and oxidative metabolic
indexes. QF (predominantly white ﬁbers) and BF (pre-
dominantly red ﬁbers) blood ﬂow indexes (Fig. 3A and B)
tended to be lower in type 2 diabetic subjects than in CON
(QF: 0.21 6 0.07 vs. 0.32 6 0.04 min, P = 0.17; BF: 0.22 6
0.05 vs. 0.33 6 0.05 min, P = 0.17). There was no signiﬁcant
difference in blood ﬂow index between QF and BF in both
groups of participants. Skeletal muscle oxidative metabo-
lism indexes (Fig. 3C and D) were similar in type 2 diabetic
subjects and CON (QF: 0.27 6 0.11 vs. 0.44 6 0.24 min, P =
0.93; BF: 0.15 6 0.09 vs. 0.20 6 0.08 min, P = 0.66).
Thigh skeletal muscle and subcutaneous adipose
tissue NEFA fractional extraction and net NEFA
uptake. NEFA fractional extraction in thigh skeletal
muscles (Fig. 4A and B) was signiﬁcantly decreased (by
;56%) in type 2 diabetic subjects versus CON (QF: 0.019 6
0.003 vs. 0.040 6 0.008 min, P = 0.03; BF: 0.019 6 0.003 vs.
0.045 6 0.011 min, P = 0.04) and tended to be decreased
FIG. 2. Plasma glucose (A), insulin (B), NEFAs (C), and TGs (D) over time during the experimental protocol in the CON (○) and type 2 diabetic
participants (●). Data are means 6 SEM.
FIG. 1. Study protocol. ct, computed tomography acquisition; dyn, dynamic PET acquisition. The dots depict timing of blood samples.
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versus CON (Fig. 4C: 0.010 6 0.002 vs. 0.018 6 0.004 min,
P = 0.07). However, NEFA uptake in thigh skeletal muscles
(Fig. 4D and E) was similar in type 2 diabetic subjects and
CON (QF: 1.47 6 0.23 vs. 1.37 6 0.24 nmol $ g
21 $ min
21,
P = 0.77; BF: 1.54 6 0.26 vs. 1.46 6 0.28 nmol $ g
21 $ min
21,
P = 0.85). NEFA uptake in subcutaneous adipose tissue was
also similar in type 2 diabetic subjects versus CON (Fig. 4F:
0.67 6 0.15 vs. 0.52 6 0.10 nmol $ g
21 $ min
21, P =0 . 4 7 ) .
NEFA fractional extraction in leg subcutaneous fat was
negatively correlated with BMI (Fig. 5A; r = 20.69, P ,
0.01), but not with nonlean mass (r = 20.30, P =0 . 3 0 )o r%
fat mass (r = 20.34, P = 0.23). NEFA fractional extraction in
skeletal muscles was positively correlated with muscle
blood ﬂow index (Fig. 5B and C;Q F :r =0 . 7 0 ,P = 0.02; BF:
r = 0.71, P = 0.02). We found a signiﬁcant correlation between
muscle blood ﬂow index and NEFA fractional extraction
in healthy subjects but not in subjects with type 2 diabetes in
both muscles (QF: r =0 . 8 8 ,P = 0.02, and r = 0.33, P =0 . 5 9 ,i n
CON and type 2 diabetic subjects, respectively; BF: r = 0.99,
P , 0.001, and r = 0.27, P = 0.66, in CON and type 2 diabetic
subjects, respectively). There was no signiﬁcant difference in
NEFA fractional extraction and NEFA uptake between QF
a n dB Fi nb o t hg r o u p so fp a r t i c i p a n t s .W ef o u n dn os i g n i ﬁ-
cant relationship between muscle blood ﬂow index and net
muscle NEFA uptake (QF: r = 20.14, P = 0.71; BF: r = 0.54,
P = 0.11) or between muscle NEFA fractional extraction and
plasma NEFA level or muscle NEFA delivery (NEFA 3
muscle NEFA blood ﬂow index) (not shown).
DISCUSSION
The current study demonstrated that postprandial NEFA
uptake in femoral skeletal muscle and subcutaneous
adipose tissue is similar in type 2 diabetic subjects com-
pared with healthy subjects despite increased circulating
NEFA levels in the former. The rate of total muscle NEFA
uptake reported herein using
18FTHA PET/CT scanning in
healthy men is compatible with the range of oxidative and
nonoxidative muscle NEFA uptake reported during fasting
by other groups using stable isotopic tracers and muscle
biopsies or arterio-venous gradient (23,24). However, di-
rect comparison between our technique and the later is
difﬁcult, since the current study reports total muscle
NEFA uptake during the postprandial state. Remarkably,
there was reduced muscle NEFA fractional extraction in
type 2 diabetes that was directly related to reduction in
muscle blood ﬂow index during the postprandial state.
This result was observed despite acute correction of
postprandial hyperglycemia in type 2 diabetes using the
insulin clamp. The present results suggest that the circu-
lating NEFA pool is an unlikely source for the excess
postprandial IMTG deposition observed in type 2 diabetes
(4). Our results lend indirect support for an important role
of excessive uptake of dietary TG in muscle in type 2 di-
abetes, as we recently demonstrated in the myocardium of
diabetic rats (17).
Lipotoxicity refers to the process leading to end-organ
damage and/or dysfunction after excess exposure to fatty
acids and was ﬁrst coined in the context of fat-induced
insulin resistance and impaired glucose-stimulated insulin
secretion leading to type 2 diabetes. Increased post-
prandial NEFA appearance rate is one of the mechanisms
that may potentially lead to increased non–adipose tissue
NEFA uptake and fatty acid exposure in type 2 diabetic
subjects (25–29). In the current study, we found no in-
crease in net skeletal muscle NEFA uptake despite the
expected increase in circulating NEFA levels during the
FIG. 3. Skeletal muscle blood ﬂow index (A and B) and oxidative metabolism index (C and D) in QF and BF, respectively, in the type 2 diabetic
participants (T2D) (■) and CON (□). Data are means 6 SEM.
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tributable to signiﬁcantly reduced muscle NEFA fractional
extraction. The results of the current study apply only to
fully established type 2 diabetes, and we cannot exclude
that muscle plasma NEFA uptake plays a role in muscle
TG accretion and lipotoxicity earlier in the natural his-
tory of type 2 diabetes. Turpeinen et al. (15) showed, also
using the
18FTHA PET method, that glucose-intolerant
subjects display decreased skeletal muscle NEFA uptake
during fasting. In the later study, this was attributable to
signiﬁcant reduction in muscle NEFA fractional extraction
with similar NEFA levels in subjects with impaired glucose
tolerance. Kelley and Simoneau (28), using arterio-venous
balance across the leg, found signiﬁcant reduction of [
3H]
oleate fractional extraction associated with reduced fat
oxidation, as assessed by limb indirect calorimetry, at
fasting and after intake of a mixed meal in type 2 diabetes.
Because circulating NEFA levels were higher, these authors
found that net NEFA uptake was nevertheless higher across
the leg in type 2 diabetes. These differences between type 2
diabetic subjects and control subjects in leg NEFA uptake
and oxidation tended to be reduced toward the end of the
6-h postprandial period. Plasma glucose levels were very
high (between 10 and 13 mmol/L) at fasting and during the
postprandial period in type 2 diabetes in the latter study,
associated with increased leg glucose oxidation that may
lead to reciprocal reduction in fatty acid oxidation (30).
Finally, it should be noted that results from limb arterio-
venous balance studies may also be inﬂuenced by tissues
other than skeletal muscles.
We found a direct relationship between blood ﬂow index
and skeletal muscle NEFA fractional extraction in the
current study, a relationship that was more apparent in
healthy individuals than in subjects with type 2 diabetes.
Insulin-resistant states are associated with reduced post-
prandial muscle blood ﬂow (31), perhaps because of
FIG. 4. NEFA fractional extraction (A, B,a n dC) and net NEFA uptake (D, E,a n dF) in QF, BF, and subcutaneous fat, respectively, in the type 2
diabetic (T2D) participants (■) and CON (□). Data are means 6 SEM. *P < 0.05 by unpaired Student t test.
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was shown in some (32,33), but not other studies (34,35),
that muscle blood ﬂow may be rate limiting for muscle
glucose uptake, at least at higher levels of insulin sensi-
tivity. We found no signiﬁcant relationship between mus-
cle blood ﬂow index and net muscle NEFA uptake or
between muscle NEFA fractional extraction and plasma
NEFA level or muscle NEFA, demonstrating no apparent
saturation of muscle NEFA transport capacity in the
present experimental conditions. However, it is not pos-
sible to establish a causal relationship between reduced
muscle blood ﬂow index and reduction in muscle NEFA
fractional extraction in subjects with type 2 diabetes, since
other sources of fatty acids such as excess circulating
TGs may compete for muscle intracellular NEFA trans-
port, leading to apparent reduction of NEFA fractional
extraction.
18FTHA has been used previously to determine abdom-
inal adipose tissue NEFA uptake in men during fasting
(19). In contrast to the clear reduction of chylomicron-
derived fatty acid uptake in subcutaneous adipose tissues
of insulin-resistant and type 2 diabetic individuals (25–
27,29), we found that postprandial adipose tissue uptake of
plasma NEFA was virtually identical in type 2 diabetic
subjects and CON. However, we found that type 2 diabetic
participants tended to have lower subcutaneous adipose
tissue NEFA fractional extraction than CON. However,
adipose tissue NEFA fractional extraction was inversely
associated with BMI in the current study, a phenomenon
perhaps attributable to reduced postprandial adipose tis-
sue blood ﬂow with obesity. In obese and/or insulin-
resistant individuals, fasting as well as postprandial increase
in subcutaneous adipose tissue blood ﬂow is lower than in
healthy normal-weight subjects (36–41). Reduction of post-
prandial adipose tissue blood ﬂow correlates with impaired
insulin sensitivity throughout the natural history of type 2
diabetes (42). Impaired postprandial adipose tissue blood
ﬂow has been related, at least in part, to impaired adipose
tissue uptake of chylomicron-derived fatty acids in morbid
obesity (43). Unfortunately, we could not assess adipose
tissue blood ﬂow index in the current study given the very
low uptake of [
11C]acetate in this tissue.
We could not ﬁnd signiﬁcant reduction of muscle oxi-
dative metabolism in type 2 diabetes. This result contrasts
with the results of others who found reduced skeletal
muscle oxidative phosphorylation in prediabetic insulin-
resistant individuals (44–46). The presence of impaired
skeletal muscle mitochondrial oxidative capacity in type 2
diabetes is controversial (47,48). In subjects with type 2
diabetes, whole-body postprandial NEFA oxidation is in-
creased, not reduced, whether glucose level is acutely
corrected or not with insulin clamp (10). It should be noted
that the [
11C]acetate method we used is based on mea-
surement of
11CO2 production from the [
11C]acetyl-CoA
intracellular pool (e.g., it is a measure of the Krebs cycle)
(13). Mitochondrial uncoupling in vivo in skeletal muscle
in type 2 diabetes could perhaps explain normal or high
Krebs cycle carbon ﬂux with reduced ATP production.
Because our sample size was small, we cannot exclude
that the lack of difference between type 2 diabetic subjects
and CON in muscle oxidative metabolism in the current
study could be due to a type 2 error.
The steady-state design of our postprandial study did not
fully reproduce physiological meal intake and may lead to
lower late postprandial overshoot of plasma NEFA level
(49). This may have attenuated differences in skeletal
muscle NEFA uptake between type 2 diabetes and CON in
the current study. On the other hand, acute correction of
postprandial hyperglycemia in type 2 diabetes is expected
to increase fatty acid oxidation at the expense of glucose
oxidation (11), leading to increased muscle fatty acid use
in the latter. We used an identical postprandial protocol
in a recent study without and with acute correction of
hyperglycemia with insulin infusion and found neverthe-
less that type 2 diabetic subjects had higher whole-body
postprandial plasma NEFA oxidation than CON in both
conditions. Another limitation of our study is that
18FTHA,
a reliable tracer of net tissue NEFA uptake (14,15,50),
FIG. 5. A: Relationship between NEFA fractional extraction in sub-
cutaneous adipose tissue and BMI. Relationship between NEFA frac-
tional extraction and blood ﬂow index in QF (B) and BF (C). CON (○)
and type 2 diabetic participants (●) are shown.
S.M. LABBÉ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 413cannot distinguish oxidative versus nonoxidative tissue
NEFA metabolism. We previously found elevated whole-
body NEFA and net fatty acid oxidation during the post-
prandial state in type 2 diabetes (10). It is therefore possible
that increased postprandial plasma NEFA oxidation in type
2 diabetes is the result of increased uptake and oxidation in
other lean organs such as the heart and the liver.
In conclusion, similar postprandial skeletal muscle
NEFA uptake in type 2 diabetic and control subjects in this
study provides evidence against a major role for increased
plasma NEFA in the postprandial fat accretion observed in
muscles in type 2 diabetes. Impaired skeletal muscle blood
ﬂow leading to impaired muscle NEFA fractional extrac-
tion may explain this ﬁnding. The results of the current
study suggest that other sources of excess fatty acid up-
take such as circulating lipoprotein-TG may be responsible
for acute postprandial IMTG accumulation in type 2 di-
abetes.
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